The Latest Breaking News from Nasdaq

According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62 million.

According to Benzinga Pro, during Q1, Liberty Latin America (NASDAQ:LILA) earned $93.20 million, a 114.24% increase from the preceding quarter. Liberty Latin America's sales decreased to $1.22 billion, a 4.69% change since Q4.

Kala Pharmaceuticals Inc (NASDAQ: KALA) shares are trading higher after the company said it would sell its EYSUVIS and INVELTYS treatments for $60 million.

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) has acquired Satiogen Pharmaceuticals Inc in a cash and stock deal. The deal consideration includes 841,792 shares, 199,993 of which are subject to the achievement of a milestone, and approximately $2.8 million in cash.  Mirum will wholly own the Satiogen subsidiary, which will receive a 2% royalty. Satiogen was an…

Cal Microturbine, Capstone Green Energy Corp's (NASDAQ:CGRN) exclusive distributor for California, Hawaii, Nevada, Oregon, and Washington, has secured six orders for C65 microturbines throughout the state of California. Financial terms were not disclosed. The 16 C65 units will be installed for customers in the agriculture, oil and gas, and hospitality industries. The systems are…

Innoviva Inc (NASDAQ:INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) at $2.20 per share in cash.  Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire differentiated,…

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue…

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has received a Refusal to File (RTF) letter from FDA regarding its marketing application for Fexapotide Triflutate. Nymox's position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. In March, the company submitted a Fexapotide Triflutate application for benign prostatic…

DiDi Global Inc (NYSE:DIDI) shareholders will vote to delist from the NYSE to get its services back on to Chinese app stores for the first time in almost a year. The plan to delist comes almost a year after the company pushed ahead with a $4.4 billion initial public offering in the U.S.…